Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00345410 | Dose-Ranging Study Evaluating AVE1625 in Abdominally Obese Patients With Atherogenic Dyslipidemia | PHASE2 | COMPLETED | 345 | — | — | Jun 1, 2006 | Jun 1, 2007 | Dec 19, 2008 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| AVE1625 B | DRUG | - |
Inclusion Criteria: * Abdominal obese patients with · * Waist circumference \> 102 cm in men and \>88 cm in women * Dyslipidemia consisting of : * Triglycerides ≥ 1.50 g/L (i.e 1.69 mmol/L) and ≤ 7.0 g/L(i.e. 7.90 mmol/L)AND/OR * HDL-cholesterol \< 50 mg/dL (i.e. 1.29 mmol/L) in women and \< 4...